News + Resources
Forbes Commentary: Trump Administration Should Reverse “Anti-Merger” Approach to M&A
The culmination of flawed antitrust policies by the Federal Trade Commission (FTC) and Department of Justice (DOJ) have discouraged pro-competitive mergers that could meaningfully benefit American consumers – a growing concern raised by former FTC general counsel and...
Innovations Advanced by M&A: New Treatment Options for Migraines
For many small and early-stage life science companies, making the leap from research and development (R&D) to manufacturing and distribution of a new treatment can be an insurmountable barrier. Pfizer’s acquisition of Biohaven Pharmaceuticals, for example, accelerated the global distribution of two new migraine therapies, while also allowing the early-stage company to continue pursuing new scientific breakthroughs.
CBSA: Life Sciences M&A Fuels Growth & Innovation in Colorado
In a recent blog post, PULSE partner Colorado Bioscience Association (CBSA) highlighted the fundamental role of pro-innovation mergers and acquisitions in driving life sciences innovation and economic growth in Colorado and beyond. Read their blog post below: ...
Latest Estimates Reinforce Burden of FTC’s Final HSR Rule
The Federal Trade Commission (FTC)’s recently finalized Hart-Scott-Rodino (HSR) premerger notification rule places a significant time and cost burden on companies engaging in procompetitive mergers and acquisitions (M&A), according to top legal analyses and the...
National Venture Capital Association: FTC’s Enforcement Approach is Chilling Critical Investment in New Breakthroughs
The Federal Trade Commission (FTC)’s aggressive approach to mergers and acquisitions enforcement (M&A) is disrupting critical investment in innovation, according to National Venture Capital Association (NVCA) President Bobby Franklin, in an interview with Axios....
What They Are Saying: FTC’s Final HSR Premerger Rules Place Undue Burden on Competitive M&A Across Life Sciences
Leading organizations are expressing concern about the impact of the Federal Trade Commission (FTC)’s final Hart-Scott-Rodino (HSR) premerger notification rule, including the chilling effect it could have on biopharmaceutical and life sciences innovation. While the...
PULSE Campaign Statement on Final HSR Rules
Washington, D.C. – In response to the final Hart-Scott-Rodino (HSR) premerger notification rules released today by the Federal Trade Commission (FTC), the Partnership for the U.S. Life Science Ecosystem (PULSE) released the following statement: While we appreciate...
Bloomberg Law: “Chilling Effect” of FTC & DOJ’s Aggressive M&A Enforcement Approach
The Federal Trade Commission (FTC) and Department of Justice (DOJ)’s aggressive approach towards mergers and acquisitions (M&A) is deterring companies from pursuing deals, write Bloomberg Law reporters Justin Wise and Mahira Dayal – threatening even procompetitive...
Innovations Advanced by M&A: A First-In-Class Treatment for Hypertrophic Cardiomyopathy
Mergers and acquisitions (M&A) are a vital mechanism for transitioning treatments currently in development to approved medicines available to the patients who need them the most. In one such example, the synergies from a life science acquisition brought a revolutionary therapy for hypertrophic cardiomyopathy (HCM) to patients.
Concurrences Law & Economics: Life Sciences M&A Brings Together Complementary Resources, Expertise
For life science companies of all sizes, competitive mergers and acquisitions (M&A) serve as a critical driver in bringing new and groundbreaking treatments and cures to market. In a recent article published in Concurrences Law and Economics, economists from...